EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients

Lu Liu, Lei Wang, Wei Wang, Yansu Wang, Yanrong Wang, Na Xu, Na Li, Haifeng Liu

Frontiers in Oncology · 12.02.2026 · 16

DOI: 10.3389/fonc.2026.1683486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 12.02.2026. Verfasst von Lu Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Hematology, Jilin Cancer Hospital, Changchun, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Programmed death-1 (PD-1) and its ligand PD-L1 play critical roles in immune checkpoint regulation. This study investigated the relationship between PD-1 and PD-L1 expression on peripheral blood lymphocytes and Non- Hodgkin Lymphoma progression.

Methods

This retrospective study included patients diagnosed with Non- Hodgkin Lymphoma at Jilin Cancer Hospital between October 2013 and May 2017. PD-1 and PD-L1 expression on CD4+ and CD8+ T cells was analyzed using flow cytometry.

Results

A total of 125 non- Hodgkin Lymphoma patients (65 males and 60 females; median age, 57 years; range, 14–86 years) were included. PD-1 and PD-L1 expression on CD8+ T cells was significantly higher in patients with elevated lactate dehydrogenase (LDH) (>245 U/L) than in those with normal LDH (PD-1: 16.46% vs . 12.68%, P = 0.005; PD-L1: 9.96% vs . 7.90%, P = 0.043). PD-1 expression on CD8+ T cells was also higher in patients with bone marrow involvement compared with those without (17.62% vs . 14.56%, P = 0.039). Furthermore, PD-L1 expression on both CD4+ and CD8+ T cells was significantly lower in patients who achieved complete response (CR) compared with those with non-CR (CD4+: 11.14% vs . 18.61%, P<0.001; CD8+: 7.19% vs . 10.60%, P = 0.032). Notably, a decrease in CD4+ PD-1 levels after treatment showed a strong trend towards improved overall survival compared with cases showing increased levels (median survival not reached in the decreased group vs . 41.77 months in the increased group, P = 0.066).

Conclusion

Peripheral blood lymphocyte PD-1 and PD-L1 expression are associated with LDH levels, bone marrow involvement, and treatment response. A reduction in CD4+ PD-1 levels after treatment is associated with a trend towards improved overall survival.

Schlagwörter

Stichwörter der Autor:innen

PD-1PD-L1immune checkpointnon - Hodgkin lymphoma lymphomasurvival

Autor:innen und Institutionen

  • Department of Lymphoma and Hematology, Jilin Cancer Hospital, Changchun, China.
  • Department of Nuclear Medicine, Jilin Cancer Hospital, Changchun, China.
  • Department of Organization of Personnel Section, Jilin Cancer Hospital, Changchun, China.
  • Department of Big Data Center of Clinical, Jilin Cancer Hospital, Changchun, China.
  • The Party Committee of the Institute, Jilin Cancer Hospital, Changchun, China.

Zitieren

APA

Liu, L., Wang, L., Wang, W., Wang, Y., Wang, Y., Xu, N., Li, N., & Liu, H. (2026). Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1683486

Vancouver

Liu L, Wang L, Wang W, Wang Y, Wang Y, Xu N, et al. Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1683486

BibTeX
@article{Liu2026,
  author = {Liu, Lu and Wang, Lei and Wang, Wei and Wang, Yansu and Wang, Yanrong and Xu, Na and Li, Na and Liu, Haifeng},
  title = {Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1683486}
}
Kostenlos starten →